NCT02779257 2022-03-04
Pasireotide Treatment for Neuroendocrine Tumor
University of Maryland, Baltimore
Phase 4 Withdrawn
Clinical Trials
7 trialsNCT01385956 2020-09-28
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02775227 2020-08-24
HYPAR
Helsinki University Central Hospital
Phase 4 Active not recruiting
NCT01469572 2018-10-18
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Emory University
Phase 1 Completed
NCT01639352 2017-07-12
Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
University of Miami
Phase 2 Completed
NCT01488487 2016-04-07
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00994110 2016-02-01
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Memorial Sloan Kettering Cancer Center
Phase 3 Completed